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Diabetes Research and Clinical Practice 78 (2007) 398–404AbstractThis study was carried out to examine the incidence of diabetes and the factors associated with this in a cohort of South Indian
women 5 years after they were examined for gestational diabetes (GDM). Women (N = 630) whose GDM status was determined
(Carpenter-Coustan criteria; GDM: N = 41) delivered live babies without major anomalies at the Holdsworth Memorial Hospital,
Mysore. Of these, 526 women (GDM: N = 35) available for follow-up after 5 years underwent a 2-h oral glucose tolerance test and
detailed anthropometry. Diabetes was determined using WHO criteria, and Metabolic Syndrome using IDF criteria recommended
for south Asian women. The incidence of diabetes (37% versus 2%) and Metabolic Syndrome (60% versus 26%) was considerably
higher in women with previous GDM compared to non-GDMwomen. GDMwomen who developed diabetes had lower gestational
insulin area-under-the-curve (P = 0.05). They had larger waist-to-hip ratio, skinfolds, body mass index, and lower 30-min insulin
increment at follow-up than other GDM women. In all, history of diabetes in first-degree relatives was independently associated
with higher incidence of diabetes (P < 0.001). Our findings suggest high diabetes and cardiovascular risks in women with previous
GDM. Follow-up of these women after delivery would provide opportunities to modify adverse lifestyle factors.
# 2007 Elsevier Ireland Ltd.
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Women with previous gestational diabetes (GDM)
are at a higher risk of developing type 2 diabetes later in
life, probably because both conditions share common
risk factors [1,2]. Thus, early detection of the
modifiable risk characteristics in GDM women may* Corresponding author at: Post Box 38, Holdsworth Memorial
Hospital, Mandi Mohalla, Mysore 570021, Karnataka, India.
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Open access under CC BY license.prevent or delay the disease process, thereby improving
their quality of life.
In an earlier study, we measured glucose tolerance in
a cohort of pregnant South Indian women [3]. The
incidence of GDM (6.2%) was considerably greater
than that reported earlier in Chennai (<1%) [4] and
Kashmir in India (3.8%) [5], but less than that reported
in another recent study from Chennai (16%) [6]. The
women, who participated in the follow-up study
examining the growth and cardiovascular risk factors
in their children [7] 5 years after the index pregnancy
were reviewed to study the incidence of type 2 diabetes
in relation to their GDM status.
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2.1. Pregnancy
During 1997–1998, 830 women with no known
history of diabetes, booking consecutively into the
antenatal clinic of the Holdsworth Memorial Hospital
(HMH) in Mysore, India, had a 100-g, 3-h, oral
glucose tolerance test (OGTT) at 30  2 weeks
gestation; 785 women completed the OGTT [3].
Socio-economic status was assessed using the Kup-
puswamy score, a questionnaire method, based on
education, occupation and income [8]. Plasma glucose
and insulin concentrations were measured as pre-
viously described [3]. GDM was diagnosed (N = 49,
6.2%) using the Carpenter and Coustan criteria [9].
Women’s own consultant obstetricians managed their
further clinical care. Of the 785 women, 630 who
chose HMH for delivery gave birth to live babies
without major anomalies and were included for further
follow-up; 41 of these women had GDM and 12 of
them were treated with insulin.
2.2. Follow-up
Further examination of these women was based on
the follow-up of their offspring. Twenty-five children
died between birth and 5 years, seven children were
excluded after birth due to medical reasons, and 43
families either refused follow-up or moved away from
Mysore. Accordingly 555 women were available for
follow-up after 5 years. All willing, non-pregnant
women, who had not been pregnant within the previous
6 months (N = 526) had a 2-h, 75-g OGTT; 524 women
completed the test. Blood was taken fasting for plasma
glucose, insulin, HDL-cholesterol and triglyceride
concentrations, and 120 min after glucose load for
plasma glucose and insulin. Women diagnosed with
GDM at the index pregnancy (N = 35) also had a 30-min
post-load sample. Weight; height; waist and hip
circumferences; biceps, triceps, subscapular and suprai-
liac skinfold thicknesses were measured using standar-
dized methods. Sum of skinfolds was obtained by
adding individual skinfolds. Systolic (SBP) and
diastolic blood pressures (DBP) were measured using
an automated (CRITIKON, DINAMAPTM model 8100,
FL, USA) BP monitor.
Glucose (glucose oxidase-peroxidase method), tri-
glycerides (GPO-PAP method) and HDL-cholesterol
(direct HDL-cholesterol method) were measured on an
autoanalyzer (Abbott laboratories, USA), and insulin
was measured using a time-resolved, fluoroimmunoas-say (DELFIA) method (Southampton, UK) at the
Diabetic Research Centre, KEM Hospital, Pune, India.
Samples were stored at 80 8C until transfer to Pune.
Only fasting samples were taken from one of two
women known to have already developed diabetes; the
other with previous GDM underwent a complete OGTT
as she did not reveal the diagnosis until after the
investigations.
Diabetes was defined as a fasting glucose concen-
tration 7.0, and/or 120-min glucose 11.1 mmol/l
(WHO criteria) [10]. Women were also classified as
having diabetes if they had been diagnosed by a doctor
as having diabetes since the index pregnancy. Impaired
glucose tolerance (IGT) was a fasting glucose
concentration <7.0 mmol/l and 120-min gluco-
se  7.8 mmol/l, but <11.1 mmol/l. Impaired fasting
glucose (IFG) was defined as a fasting glucose value of
6.1 mmol/l, but <7.0 mmol/l [10].
Metabolic syndrome was defined by the IDF
criteria recommended for south Asian women [11].
Waist circumference  80 cm, and any two of the
following: triglyceride  1.7 mmol/l; HDL-cholester-
ol < 1.29 mmol/l; SBP  130 or DBP  85 or having
treatment for hypertension; fasting glucose 
5.6 mmol/l or type 2 diabetes.
The hospital ethical committee approved the study,
and informed verbal consent was obtained from the
women.
2.3. Statistical methods
Insulin resistance was estimated using the Home-
ostasis Model Assessment equation (IR-HOMA) [12].
Insulin increment (a measure of insulin secretion) was
derived using the formula: (30-min insulin-fasting
insulin)/30-min glucose for all women during preg-
nancy, and for women with previous GDM at follow-up
[13]. Using the OGTT data collected during pregnancy,
area-under-the-curve values were calculated for glucose
(GAUC) and insulin (IAUC) concentrations using the
trapezoid rule [14]. GAUC, IAUC, IR-HOMA and
insulin increment at the index pregnancy, and fasting
glucose and triglycerides at follow-up were log-
transformed to normality.
Differences in the prevalence of diabetes, IGT/IFG
and Metabolic Syndrome between groups were ana-
lysed using chi-square tests. Differences in character-
istics among women with diabetes, IGT/IFG and
normal glucose tolerance (NGT) were examined using
one-way ANOVA with linear trend tests. Logistic
regressions were used to examine the predictors of
diabetes at follow-up in all women.
G
.V
.
K
rish
n
a
ven
i
et
a
l./D
ia
b
etes
R
esea
rch
a
n
d
C
lin
ica
l
P
ra
ctice
7
8
(2
0
0
7
)
3
9
8
–
4
0
4
4
0
0
Table 1
Characteristics of women with and without GDM during the index pregnancy
GDM in index pregnancy No GDM in index pregnancy P3
NGT (11) IGT/IFG (11) DM (13) P1 P2 NGT (406) IGT/IFG (75) DM (8)
Pregnancy
GAUC (mmol)a 1600.9 (1521, 1665) 1610.5 (1550, 1782) 1890.5 (1533, 2569) 0.07 <0.001 1081.2 (982, 1196) 1172.0 (1050, 1262) 1106.7 (933, 1283) 0.001
IAUC/104 (pmol)a 7.9 (5.5, 10.7) 8.7 (6.2, 11.2) 4.9 (2.5, 7.6) 0.05 0.5 5.1 (3.5, 7.3) 5.0 (3.6, 7.2) 4.3 (2.6, 6.4) 0.7
Fasting glucose (mmol/l) 5.2 (5.0,5.8) 5.3 (4.8, 5.7) 6.1 (4.9, 6.9) 0.09 0.03 4.5 (4.2, 4.7) 4.6 (4.4, 4.9) 4.3 (3.9, 5.0) 0.04
HOMAa 1.9 (1.0, 2.8) 2.1 (1.5, 3.3) 2.1 (1.2, 3.6) 0.7 0.5 1.1 (0.8, 1.6) 1.3 (0.9, 1.8) 1.0 (0.6, 2.1) 0.04
Insulin increment
(pmol/mmol)
21.6 (10.4) 31.5 (15.4) 18.2 (12.3) 0.5 <0.001 54.4 (35.8) 39.0 (24.0) 34.7 (11.2) 0.008
Insulin therapy (N)a,b 0 (0%) 3 (27.3%) 4 (30.8%) 0.07 – – – – –
Parity 2+ (N)a,b 1 (9%) 2 (18%) 3 (23%) 0.2 0.04 65 (16%) 14 (19%) 4 (50%) 0.2
Follow-up
Age (years)a 32.2 (28.0, 36.0) 34.0 (30.0, 38.0) 33.5 (29.5, 38.5) 0.5 0.03 28.1 (25.0, 31.0) 29.3 (27.0, 31.0) 28.6 (27.3, 30.0) 0.01
BMI (kg/m2) 23.6 (4.4) 26.1 (3.0) 26.7 (4.6) 0.08 <0.001 23.2 (4.4) 24.8 (4.4) 28.9 (4.9) 0.3
Height (cm) 153.9 (7.9) 150.8 (6.5) 152.6 (5.0) 0.7 0.02 154.8 (5.3) 153.3 (5.2) 153.2 (5.1) 0.8
Waist–hip ratio 0.87 (0.06) 0.90 (0.08) 0.93 (0.05) 0.04 <0.001 0.88 (0.07) 0.92 (0.07) 0.95 (0.09) 0.5
Sum of skinfolds (mm) 88.2 (39.9) 122.8 (18.6) 116.6 (41.5) 0.08 <0.001 92.1 (39.9) 108.2 (35.3) 135.7 (38.0) 0.4
HOMAa 1.8 (1.1, 2.6) 2.4 (1.9, 3.5) 3.6 (2.1, 5.7) 0.02 <0.001 1.6 (1.1, 2.4) 2.3 (1.6, 3.7) 4.6 (3.6, 6.4) 0.4
Insulin increment
(pmol/mmol)a
30.5 (20.6, 34.8) 27.7 (17.5, 38.9) 6.9 (0.3, 11.6) 0.001 – – – – –
Family history (N)a,b 5 (46%) 3 (27%) 12 (92%) 0.02 0.004 101 (25%) 27 (36%) 5 (63%) 0.1
Values are mean (S.D.).
a Geometric mean (IQR) or N (%). P values derived using ANOVA for linear trend for P1 GDM group, P2 non-GDM group.
b P values derived using chi-square test for linear association. P3 for difference between GDM and non-GDM diabetic women.
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Two out of the 524 women (1 GDM at the index
pregnancy, and 1 non-GDM woman who developed
GDM in the subsequent pregnancy), who presented with
symptoms since the index delivery had been diagnosed
with type 2 diabetes by a doctor, and both were on
treatment with oral sulfonylureas. At follow-up, we
diagnosed diabetes in a further 12 women who had
GDM in the index pregnancy (37%) and 7 non-GDM
women (2%; OR = 35.5, 95% CI: 13.3–94.6,
P < 0.001). The prevalence of IGT/IFG (31%; OR =
5.4, 95% CI: 2.3–12.9; P < 0.001) and Metabolic
Syndrome (60%; OR = 4.4, 95% CI: 2.2–8.9,
P < 0.001) was higher in women with previous
GDM, compared with 15% and 26%, respectively in
women who did not have GDM.
3.1. Women with GDM
Women with previous GDMwho developed diabetes
at follow-up had lower IAUC and higher GAUC during
the index pregnancy compared to either IGT/IFG orTable 2
Indices of the Metabolic Syndrome at follow-up in women with and witho
GDM in index pregnancy
NGT (11) IGT/IFG (11) DM (13) P
Waist circumference
(cm)
81.2 (10.0) 85.8 (8.6) 88.9 (9.2)
Fasting glucose
(mmol/l)a
5.3 (5.2, 5.8) 6.0 (5.8, 6.1) 10.6 (7.2, 14.3) <
Triglycerides
(mmol/l)a
0.9 (0.8, 1.4) 1.3 (0.7, 1.8) 1.8 (1.2, 3.4)
HDL cholesterol
(mmol/l)
1.15 (0.1) 1.14 (0.2) 0.98 (0.2)
Systolic BP
(mmHg)
106.7 (10.3) 125.4 (19.1) 121.1 (22.5)
Diastolic BP
(mmHg)
63.8 (8.3) 73.5 (15.9) 72.5 (11.5)
yN (%) in each defining component of the Metabolic Syndrome
Component 1 6 (54.5%) 8 (72.7%) 11 (84.6%)
2 4 (36.4%) 10 (90.9%) 13 (100%) <
3 0 (0%) 5 (45.5%) 5 (38.5%)
4 9 (81.8%) 9 (81.8%) 13 (100%)
5 1 (9.1%) 4 (36.4%) 2 (15.4%)
Metabolic
syndrome (N)
2 (18.2%) 8 (72.7%) 11 (84.6%)
Values are mean (S.D.). P values derived using ANOVA or y chi-square test
difference between GDM and non-GDM diabetic women. Metabolic Sy
glucose  5.6 mmol/l or type 2 diabetes; (3) plasma triglycerides  1.7 mmo
or diastolic BP  85 mmHg or treatment for hypertension.
a Geometric mean (IQR) or N (%).NGT women (Table 1). They were also more insulin
resistant and had lower 30-min insulin increment than
non-GDM women who developed diabetes subse-
quently. Similar proportions of diabetic and IGT/IFG
women were treated with insulin, while none of the
NGT women had insulin during pregnancy. Women
who had developed diabetes were more likely to be
multiparous (parity  2) than NGT women, but the
association was not statistically significant in these
small numbers of women (Table 1).
At follow-up, GDM women who developed diabetes
had larger body mass index (BMI), waist-to-hip ratio
(WHR) and sum of skinfolds, were more insulin
resistant, and had significantly lower insulin increment
than IGT/IFG and NGT women (Table 1).
HDL-cholesterol concentrations were lower and the
other indices of Metabolic Syndrome, and the
prevalence of Metabolic Syndrome itself were higher
in the women with diabetes at follow-up (Table 2).
Diabetes was present in first-degree relatives in 92%
(OR = 21.0, 95% CI: 2.3–192.8, P = 0.007) and
Metabolic Syndrome was present in 85% of the diabetic
women (OR = 6.6, 95% CI: 1.2–37.0, P = 0.03).ut GDM during the index pregnancy
No GDM in index pregnancy P3
1 P2 NGT (406) IGT/IFG (75) DM (8)
0.052 <0.001 81.0 (11.5) 86.2 (11.8) 96.9 (16.0) 0.2
0.001 <0.001 5.2 (4.9, 5.6) 6.1 (5.8, 6.4) 7.5 (6.0, 9.5) 0.02
0.003 0.004 1.0 (0.7, 1.4) 1.1 (0.8, 1.5) 1.5 (0.9, 2.2) 0.8
0.03 0.07 1.14 (0.2) 1.09 (0.2) 1.11 (0.2) 0.7
0.08 <0.001 107.2 (9.8) 112.8 (12.1) 117.7 (14.1) 0.3
0.1 0.001 64.8 (8.9) 68.6 (10.0) 68.2 (11.9) 0.6
0.1 <0.001 213 (52.5%) 52 (69.3%) 8 (100%) 0.4
0.001 <0.001 109 (26.8%) 64 (85.3%) 8 (100%) –
0.05 0.01 58 (14.4%) 15 (20%) 4 (50%) 0.5
0.2 0.7 300 (74.6%) 60 (80%) 5 (62.5%) 0.04
0.8 <0.001 8 (2%) 10 (13.3%) 1 (12.5%) 0.7
0.001 <0.001 75 (18.7%) 44 (58.7%) 6 (75%) 0.5
for linear association for P1 GDM group, P2 non-GDM group. P3 for
ndrome components: (1) waist circumference  80 cm; (2) fasting
l/l; (4) plasma HDL cholesterol < 1.29 mmol/l; (5) systolic BP  130
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Table 3
Logistic regression analysis to test for the predictors of diabetes at follow-up in all study women
Predictors Univariate Multivariatea
Odds ratio 95% confidence
interval
P Odds ratio 95% confidence
interval
P
GDM (yes/no) 35.5 13.3–94.6 <0.001 53.0 12.3–227.3 <0.001
Current height (cm) 0.9 0.9–1.0 0.1 1.0 0.9–1.1 0.7
Current waist circumference (cm) 1.07 1.03–1.1 <0.001 1.1 1.0–1.2 0.001
Family history (yes/no) 11.5 3.8–34.7 <0.001 10.6 2.9–39.2 <0.001
Socio-economic status (score) 0.97 0.9–1.1 0.5 0.9 0.8–1.0 0.2
Age (years) 1.2 1.1–1.3 0.001 0.95 0.8–1.1 0.6
Parity (N) 1.6 1.1–2.5 0.02 1.8 0.96–3.4 0.07
Gestational GAUC (mmol) 1.005 1.003–1.01 <0.001 – – –
Gestational fasting glucose (mmol/l) 4.3 2.2–8.3 <0.001 – – –
Gestational IAUC (pmol) 0.999 0.999–1.000 0.4 – – –
Insulin increment (pmol/mmol) 0.97 0.95–0.99 0.002 – – –
a All variables shown were included in the model simultaneously.3.2. Women without GDM
In the index pregnancy, non-GDM women who later
developed diabetes had higher glucose concentrations
and a lower mean insulin increment than women who
did not develop diabetes (Table 1). The proportion of
multiparous women was higher in the group with
diabetes.
At follow-up, women with diabetes were older,
heavier (higher BMI), shorter, had largerWHR and sum
of skinfolds, more insulin resistant and more likely to
have a family history of diabetes than either IGT/IFG or
NGT women (Table 1). Components of Metabolic
Syndrome and the prevalence of Metabolic Syndrome
(75%) were increased compared to IGT/IFG and NGT
groups (Table 2).
Non-GDM women with diabetes appeared more
obese and insulin resistant than respective GDM
women, though these associations were not significant.
We have previously reported the effects of GDM in
these mothers on the birth measurements of their
newborns [3] and on the children’s growth and glucose-
insulin parameters at 5 years [7]. In the non-GDM
group, newborns of women who developed diabetes
had significantly greater mean ponderal index
compared to those born to non-diabetic mothers
(28.6 kg/m3 versus 24.9 kg/m3, P = 0.048). This
difference remained significant after adjusting for
maternal BMI and the child’s sex (P < 0.001). There
were no statistically significant differences in other
birth measurements or in anthropometry, and glucose
and insulin concentrations at 5-year follow-up in
children born to non-GDM women with and without
subsequent diabetes.3.3. Predictors of diabetes at follow-up
Univariate logistic regression analyses in all women
showed that the presence of GDM in the index
pregnancy, higher current waist circumference, a
positive family history of diabetes, older age, higher
parity, higher GUAC, and fasting plasma glucose during
pregnancy and lower insulin increment during preg-
nancy were risk factors for the development of diabetes
(Table 3). Previous GDM, higher current waist
circumference, and family history of diabetes remained
significant risk factors after adjusting for other factors.
4. Discussion
We studied a cohort of South Indian women 5 years
after they were investigated for the incidence of GDM
as part of an earlier study [3]. The incidence of diabetes,
IGT/IFG and Metabolic Syndrome was considerably
higher in women who had GDM during the index
pregnancy compared to non-GDM women. This was in
spite of our inclusion criteria based on the offspring
follow-up at 5 years after the index pregnancy resulting
in a smaller group of GDM women available that may
have resulted in an underestimation of the incidence
rates.
We used the criteria of Carpenter and Coustan to
diagnose GDM (because this was the test in routine
clinical use in the hospital) and the WHO criteria to
define diabetes at follow-up. Comparisons with NDDG
and O’Sullivan’s (Carpenter and Coustan) methods
suggest that the WHO criteria are more sensitive in
identifying GDM [15,16]. However, a study from
Kashmir in India observed no significant difference in
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Carpenter and Coustan methods [5]. Thus, there is no
reason to infer that the methods used in the study gave a
markedly different estimation of GDM and diabetes
incidence than if other methods had been used.
Women with previous GDM who later developed
diabetes had evidence of lower insulin secretion in
response to a glucose load during pregnancy compared
to women who did not develop diabetes. They also had a
strong family history of diabetes (>90%). Their high
insulin resistance and BMI at follow-up were more in
accordance with type 2 diabetes than type 1 diabetes.
Women who develop GDM are said to be in a chronic
insulin resistant state, and studies have observed higher
insulin resistance in GDM women than in non-GDM
pregnant women [17,18]. This coupled with deficient
insulin secretion suggestive of deteriorating b-cell
function underlies the development of GDM [17]. Our
data shows that our GDM women were more insulin
resistant, and also had lower insulin increment at the
index pregnancy compared non-GDM women espe-
cially those who subsequently developed diabetes.
Studies, including those using sophisticated techniques
of measuring insulin secretion have shown that first
phase insulin secretion relative to insulin resistance
during pregnancy is an important predictor of later
development of diabetes in GDM women [19,20].
Lower insulin at follow-up in our GDM women who
developed diabetes indicate more impaired b-cell
function, which may have led to the early progression
to diabetes. Unfortunately we did not measure insulin
increment in non-GDM women at follow-up; hence we
do not know whether deteriorating b-cell function was a
predictor of diabetes in them. However, these women
were more obese and insulin resistant than diabetic
women with previous GDM.
Higher parity was associated with an increase in the
risk of diabetes at follow-up in our study. Pregnancy is a
diabetogenic condition; gestational steroid hormones
induce peripheral insulin resistance, thus increasing the
stress on pancreatic beta cell function. Multiparity may
therefore hasten deterioration to diabetes [21,22].
Our results are consistent with data from other
countries that have confirmed an association between
GDM and later type 2 diabetes [1,2,23,24]. In these
studies, the incidence of diabetes varied from 2% to
70%, depending on the length of follow-up (6–8 weeks
to 28 years) [1]. Many reported a high fasting glucose
concentration during pregnancy as an important
predictor of later diabetes [1]. High pre-pregnant
weight/BMI and higher gain in weight/BMI post-
partum were also risk factors [1,24]. Hyperglycaemiaduring the 4–16 weeks post-partum has also been shown
to be a risk factor [23,24]. Thus, a post-partum OGTT
may help to identify high-risk women who need more
rigorous follow-up, and may provide scope to modify
lifestyle factors. The American Diabetes Association
recommends evaluation of glycaemic status for all
GDM women 6 weeks after delivery [25]. However,
very few of our study women had a follow-up
examination after delivery (N = 7 out of 35). Generally
low awareness regarding the risks of GDM and a sense
of ‘complacency’ (among women themselves and their
obstetricians) after the completion of pregnancy may be
reasons for poor follow-up.
According to a recent estimate, about 10–31% of
diabetes in parous women can be ascribed to previous
GDM (population attributable ratio or PAR) [26]. As the
PAR of an exposure increases with its prevalence in a
population [26], the population impact of GDM may be
large in countries like India. A recent report showed a
high incidence of GDM [16%] among urban women in
India [6]. Considering the large population, universality
of marriage and childbearing in India, and high rates of
GDM, a large proportion of diabetes among women
may be detected early by proper screening for GDM and
follow-up of GDM women post-partum.
Unfortunately, countries like India which are still
struggling with poverty-related health risks, give little
priority to detection and management of GDM and risk
factors for type 2 diabetes. These issues are directly
related to inadequacy of funds, specialist personnel and
specialist laboratories, and lack of public awareness of
the harmful effects of GDM. Our study highlights the
need to educate the public in India about the long-term
risks associated with GDM, at the same time stressing
the need for better diagnostic and treatment protocols/
facilities for gestational diabetes in public hospitals.
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